AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06719947 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated HD-tDCS
Description: 10 sessions of sham anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) over the cortical representation zone of the left diaphragmatic motor cortex. The device will provide a 30-second ramp and then maintain a minimal, non-effective continuous current
Study NCT01997268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil
Study NCT01997268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 2 capsules
Study NCT01997268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 4 capsules
Study NCT01997268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 6 capsules
Study NCT04692324 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of CSF samples
Study NCT04692324 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT06452043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PARC program
Description: Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
Study NCT04692324 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04276740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MitoQ
Description: MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~* MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~* MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~* MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~* MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~* Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing.
Study NCT04276740 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05709184 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lyophilized fecal microbiome transfer
Description: Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
Study NCT05709184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Ten days of oral vancomycin 125 mg four times daily
Study NCT05713123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A SPECT-CT whole body is added in VERITON-CT camera
Description: A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
Study NCT05173532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: static and dynamic balance and gait stability exercises
Study NCT05891938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2 gas inhalation
Description: H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
Study NCT05173532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing and Stretching Exercises
Description: static stretching while performing diaphragmatic breathing
Study NCT06324292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: complete denture, CG
Description: fabrication of conventional complete denture followed by a digital denture
Study NCT06177925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
Study NCT06177925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Cisplatin
Description: Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
Study NCT06177925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
Study NCT06177925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
Study NCT06324292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: complete denture, DG
Description: fabrication of digital complete denture followed by a conventional one
Study NCT05218642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX- 826 dosed at 2.5mg
Description: 2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Study NCT05218642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 5mg
Description: 5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
Study NCT05218642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 dosed at 5mg
Description: 5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
Study NCT05218642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to KX-826
Description: Placebo applied topically to scalp twice daily or once daily for 24 weeks
Study NCT05126966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
Study NCT05126966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
Study NCT05126966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Delivery System with ranibizumab (PDS)
Description: PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
Study NCT05727696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Henry approach; volar approach
Description: Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
Study NCT05727696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsal approach
Description: Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
Study NCT05243472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein nutritional supplement
Description: Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
Study NCT04716205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Bent Leg Raise Technique
Description: Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
Study NCT04716205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: It will be given in supine position by performing passive SLR and end range will hold in 30sec.
Study NCT04716205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: It will be given in supine position by performing passive SLR and end range will hold in 30sec.
Study NCT06219499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-841
Description: ONC-841 is a humanized monoclonal antibody.
Study NCT06219499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05557266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
Study NCT05557266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
Study NCT06619444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only
Description: Aerobic exercise training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year trial
Study NCT06619444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30 min of resistance exercise
Description: 30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 15 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
Study NCT06619444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60 min of resistance exercise
Description: 60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
Study NCT06619444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 120 min of resistance exercise
Description: 120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
Study NCT05594407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine-ketamine-lidocaine
Description: In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
Study NCT05594407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Study NCT06679920 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical coherence tomography
Description: Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
Study NCT06509113 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The online HIV-related stigma training
Description: The intervention is an online HIV-related stigma training that takes 6 hours in 4 weeks to be completed.
Study NCT06509113 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The online HIV epidemiology training with no specific content on stigma
Description: Nursing students will be trained in an online HIV epidemiology training with no specific content on stigma. It will take 6 hours in 4 weeks to complete the training.
Study NCT06241105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib+Toripalimab.
Description: Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
Study NCT04550494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04550494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04550494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04550494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04550494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT04741165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT04741165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT04741165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally once a day during each 21-day cycle
Study NCT04944849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reaction Time Tests
Description: While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
Study NCT04875091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready SET Health
Description: This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress.
Study NCT06308523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 150 μg
Description: AP303 Tablet 150 μg QD
Study NCT06308523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 μg
Description: Placebo Tablet 150 μg QD
Study NCT06308523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 300 μg
Description: AP303 Tablet 300 μg QD
Study NCT06308523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300 μg
Description: Placebo Tablet 300 μg QD
Study NCT06694935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QX1206
Description: QX1206 will be administered orally before bedtime
Study NCT06716710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy group
Description: In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, a mandala coloring session will be held 3 days a week, 2 times a week under the supervision of the researcher. In order to ensure standardization in the pregnant women included in the study group, each pregnant woman will be given the same mandala work box (36 colored coloring pencils, file, eraser, pencil sharpener and the same mandala prints for all pregnant women). The selection of mandala patterns will be determined by the researchers. In the second week of the training, the researcher will evaluate the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of birth scale. At the end of the four-week activity, the researcher will evaluate again.
Study NCT06716710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: In addition to the medical treatments that the pregnant women in the control group will receive in the clinic for 4 weeks, no other application will be made. After two weeks, the researcher will evaluate them using the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of childbirth scale. At the end of the fourth week, the researcher will evaluate them again.
Study NCT06723626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Ascorbic acid group will receive intravenous vitamin C.
Study NCT06723626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive intravenous NS or 5% GS.
Study NCT06724211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment bundle of care
Description: The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure > 75 mmHg, identify and treat blood glucose > 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
Study NCT06724211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Routine clinical care for kidney transplant patients
Study NCT06724445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thabo cartoon
Description: The animated cartoon features Thabo, a Black South African man living with HIV. Through his narrative, viewers follow his daily experiences managing his condition and confronting societal stigma in a South African context. The story explores his interactions with family, friends, and community members, highlighting both challenges and moments of resilience. The animation concludes with Thabo delivering an anti-stigma message directly to viewers.
Study NCT06724445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Steve cartoon
Description: The animated cartoon follows Steve, a White man living with HIV. His narrative parallels Thabo's, showing his daily experiences managing HIV and facing societal stigma. The story depicts his interactions with family, friends, and community members, presenting the same situations and challenges as in Thabo's story. The animation ends with Steve delivering the same anti-stigma message to viewers.
Study NCT06722898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: Contains ingredients believed to reduce Blood Alcohol Concentration and symptoms of alcohol impairment.
Study NCT06722898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06724653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAS blocker tapering group
Description: RAS blocker tapering out
Study NCT06724653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RAS blocker tapering group
Description: RAS blocker tapering out
Study NCT06724653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker tapering out
Description: Beta blocker tapering out group
Study NCT06724653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta blocker tapering out
Description: Beta blocker tapering out group